Latest News
Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic
28 September 2020 - - The last patient study visit has occurred in the Phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome, Canada-based biopharmaceutical company Aurinia Pharmace...
TILT Biotherapeutics Doses Two Patients Pass Primary Safety Endpoint in European Cancer Immunotherapy Trial
28 September 2020 - - Finnish biotechnology company TILT Biotherapeutics has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmark's Herlev hospital in Copenhage, the company said.
Genentech Presents New 2-Year Data for Evrysdi in Infants with Type 1 Spinal Muscular Atrophy
28 September 2020 - - US-based biotechnology company Genentech has reported new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi (risdiplam) in infants aged 2-7 months with symptomatic Type 1 spinal muscular atrophy, the company said....
Avrobio Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
28 September 2020 - - The European Commission has granted orphan drug designation for AVR-RD-02, US-based gene therapy company Avrobio, Inc's (NASDAQ: AVRO) investigational gene therapy for the treatment of Gaucher disease, the company said.
Oragenics Provides an Update on Funding for its SARS-CoV-2 Vaccine
28 September 2020 - - US-based vaccine developer Oragenics, Inc. (NYSE American: OGEN) has provided an update on US federal government and other funding options the company is pursuing in order to advance its SARS-CoV-2 vaccine, Terra CoV-2, the comp...